Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption

Area of Science:

• Bone biology and osteoporosis therapeutics

Background:

• Bone formation and resorption are coupled, limiting current osteoporosis treatments.
• Salt inducible kinases (SIKs) are implicated in bone metabolism.
• YKL-05-099 is a multi-kinase inhibitor targeting SIKs.

Purpose of the Study:

• To investigate the bone anabolic potential of YKL-05-099.
• To explore the role of SIK2 and SIK3 in bone mass regulation.
• To understand the dual mechanism of YKL-05-099.

Main Methods:

• Administration of YKL-05-099 to hypogonadal female mice.
• Generation of mice with inducible global deletion of SIK2 and SIK3.
• In silico modeling of YKL-05-099 binding to SIK2 and CSF1R.

Main Results:

• YKL-05-099 increased bone formation without increasing bone resorption in mice.
• SIK2/SIK3 deletion increased bone mass but also bone resorption.
• YKL-05-099 inhibits both SIKs and CSF1R, with similar binding modes.
• Dual targeting overcomes limitations of current anabolic osteoporosis therapies.

Conclusions:

• YKL-05-099 represents a novel anabolic agent for osteoporosis.
• Targeting SIKs and CSF1R simultaneously promotes bone formation without resorption.
• This dual-targeting strategy may offer improved efficacy for osteoporosis treatment.